BofA cuts McKesson stock price target on GLP-1 headwinds

BofA cut McKesson's price target to $1,000 from $1,040 while keeping a Buy (shares at $884); analyst targets span $860–$1,107 and Argus raised its PT to $1,050. BofA warns rapid growth of cash-pay GLP‑1s (Wegovy, Zepbound) could push insurance-eligible prescriptions to between -10% and +10% in fiscal 2027, pressure take-rates (flat-to-down) and risk Prescription Technology Solutions EBIT falling short; stock P/E is 25.41 and 12 analysts recently raised earnings estimates. CFO Britt Vitalone will retire after 20 years with Kenny Cheung named successor effective May 29, 2026; Leerink ($1,085) and Evercore ($1,000) maintained Outperform/Buy ratings while BofA and others continue to weigh the guidance risk.

Analysis

The structural move of GLP-1 prescriptions toward cash-pay creates a margin squeeze that is not linear — distributors’ take-rates are sticky downward and the mechanical effect is an earnings mix shift away from high-take-rate, insurance-mediated scripts toward low-margin cash flows. A sustained 5%–10% shift in insurance-eligible scripts would likely shave mid-single-digit percentage points off Prescription Technology Solutions EBIT growth in the first 12–18 months, materially compressing free cash flow available for separation-related transaction costs.

Second-order winners include vertically integrated manufacturers and specialty pharmacies that can capture margin by routing scripts direct-to-consumer or owning fulfillment; losers are intermediaries with per-script revenue models and long receivable cycles, where lower net insurance prices increase days-sales-outstanding and working-capital volatility. The planned Medical‑Surgical separation amplifies both upside optionality and short-term execution risk — a clean carve‑out could re-rate the remaining business, but a drag from separation costs, litigation reserve reclassification or impaired receivables can push revisions sharply lower in a single quarter.

Key catalysts to watch over the next 3–12 months are (1) pace of cash-price deflation for GLP‑1s, (2) PBM or payer policy responses (prior‑auth tweaks or reimbursement resets), and (3) disclosure around separation timing/costs and transitional service agreements. The consensus underestimates the timing asymmetry: take‑rate compression hits quickly, while a re‑rating for separation value realization takes quarters to materialize — meaning event-driven volatility presents asymmetric option-like opportunities for active positioning.

Key Decisions for Investors

• Pair trade (6–12 months): Go long MCK equity (relative overweight) and short AmerisourceBergen (ABC) at a 1:1 notional ratio to isolate idiosyncratic separation/re‑rating upside while hedging industry-wide GLP‑1 take‑rate deterioration. Target relative return +20–30% if MCK execution on separation is clean; size so max portfolio exposure = 2–4% NAV and set stop if pair underperforms by 12%.
• Downside insurance (9–12 months): Buy MCK 10–15% OTM puts (or a put spread to limit premium) sized to protect 2–3% of NAV against a negative surprise from separation costs or accelerating take‑rate erosion. Cost is the insurance premium; payoff is asymmetric protection against a rapid re‑rating lower.
• Asymmetric upside (12–18 months): Purchase a MCK call spread (long 30% OTM, short 60% OTM) to express a successful separation/re‑rate thesis with defined risk. Expect 3–6x return if separation execution and analyst revisions drive multiple expansion; loss limited to premium paid.
• Tactical short (3–9 months): Short pure-play prescription‑tech/specialty pharmacy names that rely on per‑script take rates and show rising DSO or inventory risk; target names with little balance-sheet flexibility and high exposure to cash-pay GLP‑1s. Time horizon is near-term earnings cycles — cover into any payer policy intervention or stabilization in cash pricing.